Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model

• Published in: BMC cancer Vol. 24; no. 1; pp. 136 - 11
• Main Authors: Hung, Yi-Ping, Tu, Chia-Chun, Lai, Jiun-I, Yang, Muh-Hwa, Lee, Jan-Mou, Chao, Yee
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.01.2024; BioMed Central; BMC
• Subjects: Adoptive cell therapy; Allografts; Allografts - metabolism; Analysis; Animals; Antibodies; Antigen-presenting cells; Antigens; B7-H1 Antigen - metabolism; Care and treatment; CD4 antigen; CD8 antigen; Cell death; Cell Line, Tumor; Cell therapy; Colony-stimulating factor; Cytotoxicity; Dendritic Cells; Diagnosis; Female; Flow cytometry; Health aspects; Immune checkpoint inhibitor; Immune checkpoint inhibitors; Immune system; Immunotherapy; Interleukin 15; Killer cells; Killer Cells, Natural; Laboratory animals; Leukocyte migration; Leukocytes (granulocytic); Lymph nodes; Lymphatic system; Lymphocytes; Lymphocytes T; Lymphoma; Metastases; Mice; Mice, Inbred C57BL; Monocytes; Natural killer cells; Neoplasms; NKDC; Non-Hodgkin's lymphomas; Patient outcomes; Peripheral blood; Reagents; Testing; Tumor antigens; Tumor Microenvironment; Tumors; Taiwan; United States > US; NKDC; Immune checkpoint inhibitor; Tumor microenvironment; Adoptive cell therapy; Immunotherapy

Despite the utilization of immune checkpoint inhibitors (ICIs) in treating numerous types of cancers being approved, their efficacy in tumor control in the clinic is not satisfactory. Since adoptive cell therapy (ACT) can alter the tumor microenvironment, we hypothesized that ACT potentially synergi...